Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:4/1/2009

lacement closes. The foregoing disclosure regarding the "going concern" opinion is required under NASDAQ rules and requires that a company receiving an audit opinion that expresses doubt about the ability of the company to continue as a going concern make a public announcement disclosing the receipt of such opinion. With the anticipated proceeds from the initial closing of the private placement announced today, Sunesis believes that it has sufficient resources to fund its operations at least through the end of 2009.

Financial Highlights

  • No material revenue was recorded in the fourth quarter of 2008, compared to $1.8 million in the fourth quarter of the prior year. Revenue totaled $5.4 million for the year ended December 31, 2008, compared to $9.7 million for the year ended December 31, 2007. The decrease in revenue year-over-year was primarily due to the conclusion of the research phase of the kinase inhibitor collaboration with Biogen Idec in June 2008 and lower amortization of license fees and milestone payments from our collaboration with Merck & Co., Inc.
  • Research and development (R&D) expense was $4.6 million for the fourth quarter of 2008, compared to $8.3 million for the same period in 2007. R&D expense for the year ended December 31, 2008 totaled $26.3 million, compared to $36.1 million in 2007. The quarter-over-quarter and year-over-year decrease in R&D expense was primarily due to the termination of discovery research activities in June 2008 and decrease in clinical trial activities related to SNS-032 and SNS-314, partially offset by increased clinical trial activities related to voreloxin.
  • General and administrative (G&A) expense for the fourth quarter of 2008 was $2.2 million, compared to $2.8 million for the fourth quarter of 2007. For the year ended December 31, 2008, G&A expense was $11.5 millio
    '/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/25/2014)... 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will release ... 30, 2014, after market close on Thursday, August 14, 2014 ... the market opening on Friday, August 15, 2014, at 8:00 ... Standard Time) to review the Company,s financial results and provide ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
...  Amgen (NASDAQ: AMGN ) today announced that it ... results on Thursday, Jan. 26, 2012 after the close of ... conference call with the investment community at 2:00 p.m. Pacific ... Kevin Sharer, chairman and chief executive officer, and other members ...
... SPO Medical Inc. ( SPOM ), a ... in portable monitoring devices, announced today an update to ... strategy for fiscal 2012 primarily based on the completion ... consumer wellness devices. SPO currently has three ...
... team have shown that they can prevent, or even reverse, ... dogs. The disease in humans and dogs is caused ... severe and progressive vision loss. It is one of the ... "Every single abnormal feature that defines the disease in ...
Cached Biology Technology:Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results 2SPO Updates Shareholders on 2012 Corporate Strategy 2SPO Updates Shareholders on 2012 Corporate Strategy 3Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 2Gene therapy research from Penn Vet & Scheie Eye Inst. cures retinitis pigmentosa in dogs 3
(Date:7/27/2014)... -- Microorganisms like bacteria and fungi can evade treatment ... or antifungal drugs. These permanent mutations were once thought ... evolve. Now a new study has shown that microorganisms ... known as epimutations -- to gain the benefits of ... mechanism was discovered in a fungus called Mucor circinelloides, ...
(Date:7/27/2014)... data from over 18,000 patients, scientists have identified ... in Parkinson,s disease, including six that had not ... Nature Genetics , was partially funded by the ... scientists working in NIH laboratories. , "Unraveling the ... the multiple mechanisms involved in this complex disease, ...
(Date:7/25/2014)... and some of the smoke from those fires is drifting ... the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard the Aqua satellite ... over the Great Lakes region of the United States. ... 23, 2014 (first image feature highlighted below) clearly shows the ... In the image, it is over Manitoba and parts ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... relatively new phenomenon in shopping, digital coupons show great ... and usability of a specific type of electronic coupon ... team has found some interesting and important preliminary findings ... used them, why they used them and what problems ...
... of Pennsylvania say that species are still accumulating on ... past. In the study, published in the journal ... computational approach to infer the dynamics of species diversification ... nine patterns of diversification as alternative models, they examined ...
... This release is available in Spanish . ... known as hardening of the arteries, according to results ... with laboratory mice. The research provides the first direct ... lesions, symptomatic of atherosclerosis, from increasing in size in ...
Cached Biology News:Impending death for paper coupons? 2Impending death for paper coupons? 3Penn biologists say species accumulate on Earth at slower rates than in the past 2Blueberries help fight artery hardening, lab animal study indicates 2
... N. Fernandez and G. Butcher (1998). ... subject of much research in the immunology ... structure of MHC proteins and in their ... are now faced with the prospect of ...
DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
Biology Products: